Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (3)
Type
(
1 selected
)
Type
Guidance (784)
Guidance programme
(
2 selected
)
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (223)
COVID-19 rapid guidelines (3)
Diagnostics guidance (47)
Health technology evaluations (18)
Highly specialised technologies guidance (27)
Interventional procedures guidance (601)
Medical technologies guidance (67)
Medicines practice guidelines (5)
NICE guidelines (339)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (757)
Apply filters
Showing 1 to 50 of 784
Sort by
Date
Title
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance programme: Highly specialised technologies guidance
Remove Guidance programme: Highly specialised technologies guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)
TA568
13 March 2019
13 March 2019
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
TA373
16 December 2015
16 December 2015
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
TA563
27 February 2019
27 February 2019
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
TA810
20 July 2022
20 July 2022
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
TA725
15 September 2021
15 September 2021
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
TA259
27 June 2012
27 July 2016
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
TA387
27 April 2016
27 July 2016
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
TA721
18 August 2021
18 August 2021
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
TA814
3 August 2022
3 August 2022
Acalabrutinib for treating chronic lymphocytic leukaemia
TA689
21 April 2021
21 April 2021
Adalimumab and dexamethasone for treating non-infectious uveitis
TA460
26 July 2017
26 July 2017
Adalimumab for the treatment of adults with psoriasis
TA146
25 June 2008
25 June 2008
Adalimumab for treating moderate to severe hidradenitis suppurativa
TA392
22 June 2016
22 June 2016
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
TA455
12 July 2017
12 July 2017
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA715
14 July 2021
14 July 2021
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
TA375
26 January 2016
26 January 2016
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
TA195
25 August 2010
25 August 2010
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
TA96
22 February 2006
22 February 2006
Afamelanotide for treating erythropoietic protoporphyria
HST27
26 July 2023
26 July 2023
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
TA444
24 May 2017
24 May 2017
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
TA310
23 April 2014
23 April 2014
Aflibercept for treating choroidal neovascularisation
TA486
1 November 2017
1 November 2017
Aflibercept for treating diabetic macular oedema
TA346
22 July 2015
22 July 2015
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
TA409
28 September 2016
28 September 2016
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
TA305
26 February 2014
26 February 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
TA307
25 March 2014
25 March 2014
Aflibercept solution for injection for treating wet age‑related macular degeneration
TA294
24 July 2013
24 July 2013
Agomelatine for the treatment of major depressive episodes (terminated appraisal)
TA231
27 July 2011
27 July 2011
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
TA438
29 March 2017
29 March 2017
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
TA536
8 August 2018
8 August 2018
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis
TA312
28 May 2014
17 March 2020
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
TA393
22 June 2016
22 June 2016
Alitretinoin for the treatment of severe chronic hand eczema
TA177
26 August 2009
26 August 2009
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer
TA816
10 August 2022
10 August 2022
Alteplase for treating acute ischaemic stroke
TA264
26 September 2012
26 September 2012
Amantadine, oseltamivir and zanamivir for the treatment of influenza
TA168
25 February 2009
25 February 2009
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
TA850
14 December 2022
14 December 2022
Anakinra for treating Still's disease
TA685
31 March 2021
31 March 2021
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
TA697
12 May 2021
12 May 2021
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)
TA859
16 January 2023
16 January 2023
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)
TA793
8 June 2022
8 June 2022
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
TA740
28 October 2021
28 October 2021
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
TA741
28 October 2021
28 October 2021
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
TA275
27 February 2013
2 July 2021
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
TA245
25 January 2012
25 January 2012
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
TA341
4 June 2015
4 June 2015
Apremilast for treating active psoriatic arthritis
TA433
22 February 2017
22 February 2017
Apremilast for treating moderate to severe plaque psoriasis
TA419
23 November 2016
23 November 2016
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
TA213
26 January 2011
26 January 2011
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
TA292
24 July 2013
24 July 2013
Current page
1
2
3
…
16
Page
1
of
16
Next page
Results per page
10
25
50
All
Back to top